MCID: SCH003
MIFTS: 54

Schizophreniform Disorder

Categories: Mental diseases

Aliases & Classifications for Schizophreniform Disorder

MalaCards integrated aliases for Schizophreniform Disorder:

Name: Schizophreniform Disorder 12 73 15
Schizophreniform Disorders 54 70
Psychotic Disorders 44 70

Classifications:



External Ids:

Disease Ontology 12 DOID:11328
ICD9CM 34 295.4
MeSH 44 D011618
NCIt 50 C94376
SNOMED-CT 67 88975006
ICD10 32 F20.81
UMLS 70 C0033975 C0036358

Summaries for Schizophreniform Disorder

Disease Ontology : 12 A psychotic disorder that involves schizophrenia symptoms over time period of one month.

MalaCards based summary : Schizophreniform Disorder, also known as schizophreniform disorders, is related to tardive dyskinesia and depression, and has symptoms including photophobia, restlessness and personality changes. An important gene associated with Schizophreniform Disorder is NRG1 (Neuregulin 1), and among its related pathways/superpathways are G-Beta Gamma Signaling and Monoamine GPCRs. The drugs Guanfacine and Sibutramine have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and prefrontal cortex, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 73 Schizophreniform disorder is a mental disorder diagnosed when symptoms of schizophrenia are present for... more...

Related Diseases for Schizophreniform Disorder

Diseases related to Schizophreniform Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 260)
# Related Disease Score Top Affiliating Genes
1 tardive dyskinesia 30.7 HTR2A DRD2 COMT
2 depression 30.6 PRL HTR2C HTR2A BDNF
3 early-onset schizophrenia 30.3 DRD2 BDNF
4 cannabis abuse 30.2 PRODH NRG1 DRD2 COMT BDNF
5 polysubstance abuse 30.1 DRD2 COMT
6 melancholia 30.1 PRL HTR2A BDNF
7 neurotic disorder 30.1 HTR2A COMT BDNF
8 schizophrenia 2 30.1 PRODH DISC1
9 schizophrenia 18 30.1 PRODH NRXN1
10 post-traumatic stress disorder 30.0 NRG1 HTR2A DRD2 COMT BDNF
11 hyperprolactinemia 30.0 PRL HTR2C HTR2A DRD2
12 traumatic brain injury 29.9 DRD2 COMT BDNF
13 postpartum depression 29.9 PRL COMT BDNF
14 substance-induced psychosis 29.9 SLC6A3 HTR2C HTR2A DTNBP1 DRD2 COMT
15 sexual disorder 29.8 PRL HTR2C HTR2A BDNF
16 conduct disorder 29.7 SLC6A3 DRD2 COMT
17 schizoaffective disorder 29.7 PRODH PRL NRXN1 HTR2A DTNBP1 DRD2
18 phobia, specific 29.7 PRODH HTR2A COMT BDNF
19 hypochondriasis 29.7 HTR2C HTR2A BDNF
20 digeorge syndrome 29.7 PRODH NRXN1 DISC1 COMT
21 alcohol use disorder 29.6 SLC6A3 PRODH HTR2C HTR2A DRD2 COMT
22 endogenous depression 29.6 SLC6A3 PRL HTR2A DRD2 COMT BDNF
23 mental depression 29.6 SLC6A3 PRODH HTR2C HTR2A DRD2 DISC1
24 anorexia nervosa 29.6 PRL HTR2C HTR2A COMT BDNF
25 eating disorder 29.6 SLC6A3 HTR2C HTR2A DRD2 COMT BDNF
26 movement disease 29.6 SLC6A3 PRODH DRD2 COMT BDNF
27 dystonia 29.5 SLC6A3 PRL HTR2A DRD2 COMT BDNF
28 narcolepsy 29.5 SLC6A3 HTR2A DRD2 COMT BDNF
29 substance dependence 29.5 SLC6A3 DTNBP1 DRD2 COMT BDNF
30 asperger syndrome 29.5 NRXN1 DISC1 COMT BDNF
31 fragile x syndrome 29.4 PRODH NRXN1 DISC1 BDNF
32 dementia 29.4 SLC6A3 HTR2A DRD2 COMT BDNF
33 prader-willi syndrome 29.4 PRODH PRL HTR2C BDNF
34 obsessive-compulsive disorder 29.4 SLC6A3 PRL HTR2C HTR2A DRD2 COMT
35 social phobia 29.4 PRODH PRL HTR2A DRD2 COMT BDNF
36 substance abuse 29.4 SLC6A3 PRODH PRL HTR2A DRD2 COMT
37 speech disorder 29.4 SLC6A3 PRODH NRXN1 DRD2
38 paranoid schizophrenia 29.3 PRL NRXN1 HTR2A DISC1 COMT BDNF
39 pervasive developmental disorder 29.3 PRODH NRXN1 HTR2A DRD2 DISC1 BDNF
40 cocaine dependence 29.3 SLC6A3 HTR2A DRD2 COMT BDNF
41 delusional disorder 29.2 SLC6A3 PRODH HTR2C HTR2A DRD2 DISC1
42 anxiety 29.1 SLC6A3 PRODH PRL HTR2C HTR2A DRD2
43 alcohol dependence 29.1 SLC6A3 HTR2C HTR2A DRD2 COMT BDNF
44 parkinson disease, late-onset 29.0 SLC6A3 PRODH HTR2A DRD2 COMT BDNF
45 sleep disorder 29.0 SLC6A3 PRODH PRL HTR2C HTR2A COMT
46 personality disorder 29.0 SLC6A3 PRL HTR2C HTR2A DRD2 COMT
47 borderline personality disorder 29.0 SLC6A3 PRL HTR2C HTR2A DRD2 COMT
48 dysthymic disorder 28.9 SLC6A3 PRODH HTR2C HTR2A COMT BDNF
49 panic disorder 28.9 SLC6A3 PRL HTR2C HTR2A DRD2 DAOA
50 gilles de la tourette syndrome 28.9 SLC6A3 NRXN1 HTR2A DRD2 COMT BDNF

Comorbidity relations with Schizophreniform Disorder via Phenotypic Disease Network (PDN): (show top 50) (show all 116)


Active Peptic Ulcer Disease Acute Conjunctivitis
Acute Cystitis Acute Kidney Failure
Acute Myocardial Infarction Adjustment Disorder
Age-Related Hearing Loss Alcohol Use Disorder
Alzheimer Disease Amnestic Disorder
Antisocial Personality Disorder Anxiety
Aortic Valve Disease 1 Atypical Depressive Disorder
Bacteremia 2 Bipolar Disorder
Blepharitis Borderline Personality Disorder
Brain Cancer Bronchitis
Bronchopneumonia Bullous Pemphigoid
Cerebral Atherosclerosis Cerebral Degeneration
Cerebrovascular Disease Chronic Kidney Disease
Chronic Ulcer of Skin Communicating Hydrocephalus
Conduct Disorder Conjunctivitis
Conversion Disorder Cyclothymic Disorder
Cystitis Decubitus Ulcer
Deficiency Anemia Delusional Disorder
Dependent Personality Disorder Dermatomycosis
Dysthymic Disorder Encephalopathy
Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation Erythematosquamous Dermatosis
Esophageal Disease Esophagitis
Familial Atrial Fibrillation Folic Acid Deficiency Anemia
Generalized Anxiety Disorder Generalized Atherosclerosis
Heart Disease Hepatic Encephalopathy

Graphical network of the top 20 diseases related to Schizophreniform Disorder:



Diseases related to Schizophreniform Disorder

Symptoms & Phenotypes for Schizophreniform Disorder

UMLS symptoms related to Schizophreniform Disorder:


photophobia; restlessness; personality changes; pseudobulbar behavioral symptoms; sleep disturbances; mental and behavioral signs and symptoms; clouded consciousness; catatonic reaction

MGI Mouse Phenotypes related to Schizophreniform Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10 BDNF COMT DAO DISC1 DRD2 DTNBP1
2 homeostasis/metabolism MP:0005376 9.73 BDNF COMT DAO DISC1 DRD2 DTNBP1
3 nervous system MP:0003631 9.44 BDNF COMT DAO DISC1 DRD2 DTNBP1

Drugs & Therapeutics for Schizophreniform Disorder

Drugs for Schizophreniform Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 375)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
2
Sibutramine Approved, Illicit, Investigational, Withdrawn Phase 4 106650-56-0 5210
3
tannic acid Approved Phase 4 1401-55-4
4
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
5
Fluphenazine Approved Phase 4 69-23-8 3372
6
Asenapine Approved Phase 4 85650-56-2, 65576-45-6 3001386
7
Chlorpromazine Approved, Investigational, Vet_approved Phase 4 50-53-3 2726
8
Thioridazine Approved, Withdrawn Phase 4 50-52-2 5452
9
Amisulpride Approved, Investigational Phase 4 71675-85-9, 53583-79-2 2159
10
Fluspirilene Approved, Investigational Phase 4 1841-19-6 3396
11
Sertindole Approved, Investigational, Withdrawn Phase 4 106516-24-9 60149
12
Sulpiride Approved, Investigational Phase 4 15676-16-1 5355
13 Perazine Approved, Investigational Phase 4 84-97-9
14
Benperidol Approved, Investigational Phase 4 2062-84-2
15
bromperidol Approved, Investigational Phase 4 10457-90-6 2448
16
Norepinephrine Approved Phase 4 51-41-2 439260
17
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
18
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
19
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
20
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
21
Donepezil Approved Phase 4 120014-06-4 3152
22
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
23
Methamphetamine Approved, Illicit Phase 4 537-46-2 10836
24
Pravastatin Approved Phase 4 81093-37-0 54687
25
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
26
Cycloserine Approved Phase 4 68-41-7 401 6234
27
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
28
Amitriptyline Approved Phase 4 50-48-6 2160
29
Zinc Approved, Investigational Phase 4 7440-66-6 32051
30
Pramlintide Approved, Investigational Phase 4 151126-32-8
31
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
32
Cinnarizine Approved, Investigational Phase 4 298-57-7 1547484 2761
33
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
34
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
35
Allopurinol Approved Phase 4 315-30-0 2094
36
Cocaine Approved, Illicit Phase 4 50-36-2 446220 5760
37
Memantine Approved, Investigational Phase 4 19982-08-2 4054
38
gamma-Aminobutyric acid Approved, Investigational Phase 4 56-12-2 119
39
Brexpiprazole Approved, Investigational Phase 4 913611-97-9 11978813
40
Aripiprazole lauroxil Approved, Investigational Phase 4 1259305-29-7 49831411
41
Bazedoxifene Approved, Investigational Phase 4 198481-32-2
42
Tocopherol Approved, Investigational Phase 4 1406-66-2
43 Coconut Approved Phase 4
44
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198
45
Losartan Approved Phase 4 114798-26-4 3961
46
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
47
Promethazine Approved, Investigational Phase 4 60-87-7 4927
48
Pimavanserin Approved, Investigational Phase 4 706779-91-1 16058810
49
Hydroxyzine Approved Phase 4 68-88-2 3658
50
Propranolol Approved, Investigational Phase 4 525-66-6 4946

Interventional clinical trials:

(show top 50) (show all 1219)
# Name Status NCT ID Phase Drugs
1 A Pilot Study to Determine How Frequency of Administration Modifies Steady-State Plasma Concentrations of Orally Administered Clozapine Unknown status NCT02286206 Phase 4 Clozapine
2 A Pilot Study to Determine if Pantoprazole Modifies Steady-State Plasma Concentrations of Orally Administered Psychotropic Medications Unknown status NCT02213887 Phase 4 Pantoprazole;Pantoprazole
3 A Double Blind Placebo Controlled Study of Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia Unknown status NCT00469664 Phase 4 Guanfacine/Tenex
4 Reduction of Cardiovascular Risk in Severe Mental Illness Prescribing and Using Better and More Appropriated Drugs Unknown status NCT01182012 Phase 4
5 Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis- An Investigator-initiated, Phase IV, Randomised Double-blind Multi-centre Trial of the Benefits and Harms of Aripiprazole Versus Quetiapine in Children and Adolescents With Psychosis Unknown status NCT01119014 Phase 4 Aripiprazole;Quetiapine
6 Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: a Randomized Comparison of Aripiprazole and Risperidone Over 3 Years Unknown status NCT03883204 Phase 4 Aripiprazole;Risperidone
7 Donepezil Double Blind Trial for ECT Memory Disfunction Unknown status NCT00465283 Phase 4 Donepezil
8 Determining the Efficacy and Tolerance of Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute Psychiatry Unknown status NCT00986167 Phase 4 Quetiapine XR
9 Identifying Predictors of Response in 12 Weeks of Treatment With Antipsychotics Using a Treatment Algorithm for Schizophrenia Unknown status NCT01016145 Phase 4 Antipsychotics;Antipsychotics
10 A Study on the Efficacy, Pharmacokinetics and Adverse Effects of Paliperidone ER Unknown status NCT02433717 Phase 4 Paliperidone ER
11 Association of the Amisulpride Treatment Response in Patients With Schizophrenia With the Findings of Brain Structural Magnetic Resonance Imaging Unknown status NCT02095938 Phase 4 amisulpride
12 Effect of Varenicline on Smoking Cessation in Patients With Schizophrenia: Evaluation of Antipsychotic Drug-Induced Neurological Symptoms as Correlates of Response Unknown status NCT03495024 Phase 4 Varenicline
13 An Open-label Switch Study to Asenapine in the Early Stage of Psychosis Unknown status NCT01968161 Phase 4 Asenapine
14 The Assessment of a Anti-Obesity Agent for the Treatment of Olanzapine-Associated Weight Gain in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder and Bipolar I Disorder Completed NCT00044187 Phase 4 Sibutramine
15 Multicenter, Single Group Study of Aripiprazole Efficacy and Safety in the Acute Psychosis Treatment of Schizophrenia, Schizophreniform Disorder and Schizoaffective Disorder. Completed NCT00304655 Phase 4 Aripiprazole
16 A Multi-center, Randomized, Double Blind, Parallel, PhaseⅣ Trial to Evaluate the Efficacy and Safety of A-prexa Compared to Zyprexa in Patients With Schizophrenia, Schizophreniform Disorder and Schizoaffective Disorder Completed NCT02137993 Phase 4 A-prexa;Zyprexa
17 The Assessment of a Weight Management Program for Treatment-Emergent Weight Gain in Patients With Schizophrenia, Schizophreniform Disorder, and Schizoaffective Disorder During Olanzapine Therapy Completed NCT00485823 Phase 4 Olanzapine Hydrochloride
18 Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics for the Prevention of Relapse in Long-term Stabilized Schizophrenic Patients: a Randomized, Single-blind, Longitudinal Trial Completed NCT02307396 Phase 4 Olanzapine;Amisulpride;Risperidone;Haloperidol;Quetiapine;Perphenazine;Sulpiride;bromperidol;Zuclopenthixol;Thioridazine;Paliperidone;Ziprasidone;Benperidol;Fluspirilene;Pimozide;Perazine;Fluphenazine;Flupentixole;Sertindole
19 Treatment of Major Depressive Episodes During the Course of Psychotic Disorders With Duloxetine Completed NCT00224302 Phase 4 Duloxetine
20 Childhood Onset Psychotic Disorders: Characterization and Treatment With Atypical Neuroleptics Completed NCT00001656 Phase 4 Olanzapine;Clozapine
21 Determining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete Adherence Completed NCT00215579 Phase 4 Depot Risperidone Microsphere (Consta)
22 Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting. Completed NCT00932529 Phase 4 Olanzapine;Quetiapine;Risperidone;Ziprasidone
23 Improving Metabolic Parameters of Antipsychotic Child Treatment (IMPACT) Completed NCT00806234 Phase 4 Aripiprazole or Perphenazine;Metformin;Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine
24 An Open-labeled, Parallel-group, Single-blinded (Rater) Pilot Study to Investigate the Neuroprotective Effects of of Low-dose Lithium in Young Subjects at Ultra High Risk (UHR) of Developing a First-episode Psychotic Disorder Completed NCT00202306 Phase 4 lithium carbonate
25 Injectable Versus Oral Naltrexone Treatment of Alcohol Dependence In Serious Mental Illness (SMI): A Pilot Study Completed NCT00453804 Phase 4 injectable naltrexone;oral naltrexone
26 Injectable Naltrexone Treatment of Alcohol Dependence in Serious Mental Illness (SMI): An Open Prospective Pilot Trial Completed NCT00453609 Phase 4 long-lasting injectable naltrexone
27 A Prospective Open-label Trial of Metformin for Weight Control of Pediatric Patients on Atypical Antipsychotic Medications. Completed NCT00391261 Phase 4 Metformin
28 Effect of Addition of Modafinil on the Tolerability and Efficacy for Cognition of Atypical Antipsychotic Drugs in Patients With Schizophrenia or Schizoaffective Disorder Completed NCT00373672 Phase 4 armodafinil (Nuvigil);placebo
29 Selective Estrogen Receptor Modulators - A Potential Treatment for Psychotic Symptoms of Schizophrenia? Completed NCT00361543 Phase 4 Raloxifene hydrochloride
30 A Multicenter, Randomized, Double-blind, Placebo-controlled, 16 Week Study of Aripiprazole Used as Dual Therapy in the Treatment of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder Demonstrating an Inadequate Response to Quetiapine or Risperidone Monotherapy. Completed NCT00325689 Phase 4 Quetiapine or Risperidone + Aripiprazole;Quetiapine or Risperidone + placebo
31 Effect of Nicotine Agonist Galantamine Added to High Potency Medications for Cognitive Function in Patients With Schizophrenia and Schizoaffective Disorder Completed NCT00320736 Phase 4 galantamine
32 Nicotine Replacement Therapy Added to Cognitive Behavioral Therapy for Smoking Cessation in Patients With Major Mental Illness Completed NCT00320723 Phase 4 bupropion, transdermal nicotine patch
33 Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)? Completed NCT00306475 Phase 4 divalproex sodium ER;placebo
34 Brain Imaging and Mental Disorders of Aging Intervention Completed NCT00267163 Phase 4 donepezil;Placebo
35 Effect on Efficacy, Safety and Quality of Life by Long-Term Treatment of Long-Acting Risperidone Microspheres in Patients With Schizophrenia Completed NCT00269919 Phase 4 Risperidone Long-Acting Injectable (RLAI)
36 Prevention of NMDA Antagonist-induced Psychosis and Memory Impairment in Children Completed NCT00205712 Phase 4 Ketamine;Dexmedetomidine
37 A Multicenter, Open Label, Flexible-dose, Parallel-group Evaluation of the Cataractogenic Potential of Quetiapine Fumarate (Seroquel) and Risperidone (Risperdal) in the Long Term Treatment of Participants With Schizophrenia or Schizoaffective Disorder Completed NCT00206102 Phase 4 quetiapine fumarate;risperidone
38 Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis Completed NCT00204061 Phase 4 Amisulpride
39 A Pilot Open Trial Of Ziprasidone, Early In The Course Of Pediatric Psychotic Illness Completed NCT00199940 Phase 4 Ziprasidone
40 Efficacy of Quetiapine in Treating Patients With Active Substance Use Disorder and Schizophrenia Completed NCT00156715 Phase 4 Quetiapine
41 Pimozide Augmentation of Clozapine in Schizophrenia Completed NCT00158223 Phase 4 Pimozide;Placebo
42 Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: a Randomized Comparison of Aripiprazole, Quetiapine and Ziprasidone Over 1 Year Completed NCT02534363 Phase 4 Aripiprazole;Quetiapine;Ziprasidone
43 Evaluation of Efficacy and Safety of Risperidone in Long-acting Microspheres in Patients With Schizophrenia, Schizophreniform or Schizoaffective Disorders Diagnosed According to the DSM-IV Criteria, After Switching Treatment With Any Antipsychotic Therapy With Long-acting Microspheres of Risperidone Completed NCT01855074 Phase 4 Risperidone
44 A Pilot Study of Vitamin D Supplementation in Bronx Psychiatric Patients Completed NCT01169142 Phase 4
45 A Comparison of Long-Acting Injectable Medications for Schizophrenia Completed NCT01136772 Phase 4 haloperidol decanoate;paliperidone palmitate
46 Post Marketing Study of Escitalopram Versus Risperidone for the Treatment of Behavioral and Psychological Symptoms Amongst Alzheimer's Disease Patients Completed NCT01119638 Phase 4 Escitalopram;Risperidone
47 Evaluation of Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotic Medications Completed NCT00458211 Phase 4 ziprasidone
48 Antipsychotic Discontinuation in Alzheimer's Disease Completed NCT00417482 Phase 4 risperidone
49 A Sixteen-Week, Multi-Center, Open-Label Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone In Subjects Diagnosed With Schizophrenia Or Schizoaffective Disorder Completed NCT00406315 Phase 4 ziprasidone
50 Indicated Prevention With Omega-3 Fatty Acids in Adolescents With 'At-Risk-Mental-State' for Psychosis: A Randomised, Double Blind, Placebo-Controlled Treatment Trial Completed NCT00396643 Phase 4 Omega 3 fatty acids

Search NIH Clinical Center for Schizophreniform Disorder

Inferred drug relations via UMLS 70 / NDF-RT 51 :


acetophenazine
Acetophenazine maleate
Carbamazepine
Chlorpromazine
Chlorpromazine hydrochloride
Chlorprothixene
Clozapine
CLOZAPINE (CARACO)
CLOZAPINE (CLOZARIL)
CLOZAPINE (IVAX)
CLOZAPINE (TEVA)
CLOZAPINE (VERSACLOZ)
Droperidol
Fazaclo
Fluphenazine
fluphenazine decanoate
Fluphenazine enanthate
Fluphenazine Hydrochloride
Haloperidol
haloperidol decanoate
Haloperidol lactate
HYPERICUM PERFORATUM (ST. JOHN'S WORT)
Lorazepam
Loxapine
Loxapine hydrochloride
Loxapine Succinate
Mesoridazine
Mesoridazine besylate
Molindone
Molindone Hydrochloride
Mylan brand of clozapine
olanzapine
Perphenazine
Pimozide
Prochlorperazine
Prochlorperazine Edisylate Salt
Prochlorperazine Maleate
Promazine
Promazine Hydrochloride
quetiapine
Quetiapine fumarate
Thioridazine
Thioridazine Hydrochloride
Thiothixene
Thiothixene hydrochloride
Trifluoperazine
Trifluoperazine hydrochloride
Triflupromazine
Triflupromazine hydrochloride
UDL brand of clozapine

Cochrane evidence based reviews: psychotic disorders

Genetic Tests for Schizophreniform Disorder

Anatomical Context for Schizophreniform Disorder

MalaCards organs/tissues related to Schizophreniform Disorder:

40
Brain, Cortex, Prefrontal Cortex, Eye, Pituitary, Liver, Skin

Publications for Schizophreniform Disorder

Articles related to Schizophreniform Disorder:

(show top 50) (show all 567)
# Title Authors PMID Year
1
Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole. 61 54
18786813 2008
2
The 'Parma-Early Psychosis' programme: Characterization of help-seekers with first episode psychosis. 61
32307896 2021
3
Symptom Remission and Brain Cortical Networks at First Clinical Presentation of Psychosis: The OPTiMiSE Study. 61
33057670 2021
4
Stable habituation deficits in the early stage of psychosis: a 2-year follow-up study. 61
33414431 2021
5
Risk of Psychiatric Disorders in Multiple Sclerosis: A Nationwide Cohort Study in an Asian Population. 61
33654401 2021
6
A commentary revisiting the viral hypothesis of schizophrenia: Onset of a schizophreniform disorder subsequent to SARS CoV-2 infection. 61
33223274 2021
7
A case of extended-release Quetiapine causing recurrent low-grade fevers. 61
33246590 2021
8
Effectiveness of antipsychotic drugs in schizophrenia: a 10-year retrospective study in a Korean tertiary hospital. 61
33214559 2020
9
Hippocampal volume in early psychosis: a 2-year longitudinal study. 61
32873788 2020
10
Early treatment response in first episode psychosis: a 7-T magnetic resonance spectroscopic study of glutathione and glutamate. 61
32205866 2020
11
Rasch analysis of the PANSS negative subscale and exploration of negative symptom trajectories in first-episode schizophrenia - data from the OPTiMiSE trial. 61
32438207 2020
12
Prednisolone versus placebo addition in the treatment of patients with recent-onset psychotic disorder: a trial design. 61
32513294 2020
13
An Investigation of Psychosis Subgroups With Prognostic Validation and Exploration of Genetic Underpinnings: The PsyCourse Study. 61
32049274 2020
14
Therapeutic Drug Monitoring of Olanzapine and Cytochrome P450 Genotyping in Nonsmoking Subjects. 61
31425442 2020
15
Brief day hospital mentalization based group psychotherapy for schizophrenia spectrum disorders: A feasibility study. 61
32463912 2020
16
Effects of socio-demographic characteristics, premorbid functioning, and insight on duration of untreated psychosis in first-episode schizophrenia or schizophreniform disorder in Northern Malawi. 61
30706661 2019
17
The prevalence of schizophrenia and other psychotic disorders among homeless people: a systematic review and meta-analysis. 61
31775786 2019
18
Sex differences in event-related potential (ERP) waveforms of primary psychotic disorders: A systematic review. 61
30790596 2019
19
Informed consent and ethical reporting of research in clinical trials involving participants with psychotic disorders. 61
31247285 2019
20
Phenotypic factors associated with amisulpride-induced weight gain in first-episode psychosis patients (from the OPTiMiSE cohort). 61
31323113 2019
21
Associations between schizophrenia genetic risk, anxiety disorders and manic/hypomanic episode in a longitudinal population cohort study. 61
30472973 2019
22
Insomnia and suicidal ideation in nonaffective psychosis. 61
30407600 2019
23
Anesthesia Management of Special Patient Populations Undergoing Electroconvulsive Therapy: A Review. 61
31130568 2019
24
Screening for cognitive deficits with the Evaluation of Cognitive Processes involved in Disability in Schizophrenia scale. 61
30012064 2019
25
[Adolescent with a schizophreniform disorder and recurrent 16p11.2 duplication]. 61
31243752 2019
26
Early interventions in a US military FIRST episode psychosis program. 61
29971958 2018
27
Contribution of stress and coping strategies to problematic Internet use in patients with schizophrenia spectrum disorders. 61
30282059 2018
28
Childhood adversity and cognitive function in schizophrenia spectrum disorders and healthy controls: evidence for an association between neglect and social cognition. 61
29268811 2018
29
Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. 61
30115598 2018
30
The Psychopathology of Delusion of Control According to Subjective Experience. 61
30286844 2018
31
A causality dilemma: ARFID, malnutrition, psychosis, and hypomagnesemia. 61
30192994 2018
32
Systematic review and meta-analysis found higher levels of behavioural problems in male left-behind children aged 6-11 years. 61
29280182 2018
33
Detection of early psychotic symptoms: Validation of the Spanish version of the "Symptom Onset in Schizophrenia (SOS) inventory". 61
29287238 2018
34
Prospective Relationships Between Motivation and Functioning in Recovery After a First Episode of Schizophrenia. 61
28981811 2018
35
[Prefrontal Cortex Activity During Facial Affect Processing in Schizophrenia: Association with Clinical Symptoms and Social Cognitive Functions]. 61
30887473 2018
36
Substance abuse and gender differences in first episode psychosis: Impact on hospital readmissions. 61
28648845 2018
37
Do patients with schizophreniform and bipolar disorders show an intrathecal, polyspecific, antiviral immune response? A pilot study. 61
29212505 2017
38
Different communication strategies for disclosing a diagnosis of schizophrenia and related disorders. 61
29064090 2017
39
Autopsy-proven Mirtazapine Withdrawal-induced Mania/Hypomania Associated with Sudden Death. 61
29472753 2017
40
Peripheral blood gene expression of acute phase proteins in people with first episode psychosis. 61
28627459 2017
41
Brain volume changes over the first year of treatment in schizophrenia: relationships to antipsychotic treatment. 61
28347393 2017
42
Baseline Demographics and Characteristics From a Paliperidone Palmitate Study in Subjects with Recent-Onset Schizophrenia or Schizophreniform Disorder. 61
28839335 2017
43
Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies. 61
28540034 2017
44
Diagnostic Stability of ICD/DSM First Episode Psychosis Diagnoses: Meta-analysis. 61
26980142 2016
45
Hypocalcemia Masquerading as Schizophreniform Disorder. 61
27833232 2016
46
Seropositivity of neurotropic infectious agents in first-episode schizophrenia patients and the relationship with positive and negative symptoms. 61
27287787 2016
47
Psychosis of epilepsy: a multifaceted neuropsychiatric disorder. 61
27322691 2016
48
The McLean-Harvard First-Episode Project: Early Course in 114 Cases of First-Episode Nonaffective Psychoses. 61
27232651 2016
49
Menstrual cycle characteristics in women with persistent schizophrenia. 61
26070315 2016
50
White matter alterations associated with suicide in patients with schizophrenia or schizophreniform disorder. 61
26774424 2016

Variations for Schizophreniform Disorder

Expression for Schizophreniform Disorder

Search GEO for disease gene expression data for Schizophreniform Disorder.

Pathways for Schizophreniform Disorder

Pathways related to Schizophreniform Disorder according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.67 HTR2C HTR2A GRM3 DRD2 BDNF
2
Show member pathways
11.54 HTR2C HTR2A DRD2
3
Show member pathways
11.53 SLC6A3 GRM3 DRD2 BDNF
4 11.38 HTR2C HTR2A DRD2
5 10.67 HTR2C HTR2A
6
Show member pathways
10.49 SLC6A3 DRD2 COMT
7 10.1 PRL HTR2C DRD2

GO Terms for Schizophreniform Disorder

Cellular components related to Schizophreniform Disorder according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 10.04 SLC6A3 NRXN1 NRG1 HTR2C HTR2A GRM3
2 synapse GO:0045202 9.87 NRXN1 NRG1 HTR2C HTR2A DTNBP1 DRD2
3 dendrite GO:0030425 9.83 HTR2C HTR2A DRD2 COMT BDNF
4 postsynaptic density GO:0014069 9.81 GRM3 DTNBP1 DRD2 DISC1
5 glutamatergic synapse GO:0098978 9.77 NRG1 HTR2A GRM3 DTNBP1 DRD2
6 dendritic spine GO:0043197 9.65 ZNF804A GRM3 DTNBP1 DRD2 COMT
7 presynaptic membrane GO:0042734 9.63 SLC6A3 NRXN1 GRM3
8 dopaminergic synapse GO:0098691 9.48 SLC6A3 DRD2
9 integral component of postsynaptic membrane GO:0099055 9.46 SLC6A3 HTR2A GRM3 DRD2
10 G protein-coupled serotonin receptor complex GO:0098666 9.4 HTR2C HTR2A
11 integral component of presynaptic membrane GO:0099056 9.35 SLC6A3 NRXN1 HTR2A GRM3 DRD2
12 axon GO:0030424 9.32 ZNF804A SLC6A3 NRG1 HTR2A GRM3 DTNBP1

Biological processes related to Schizophreniform Disorder according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.19 PRL NRXN1 NRG1 HTR2C HTR2A GRM3
2 positive regulation of gene expression GO:0010628 9.93 ZNF804A POU3F1 NRXN1 NRG1 DTNBP1
3 chemical synaptic transmission GO:0007268 9.87 NRXN1 HTR2C HTR2A GRM3
4 positive regulation of neuron projection development GO:0010976 9.81 ZNF804A DISC1 BDNF
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.8 NRXN1 HTR2C HTR2A DRD2
6 cellular calcium ion homeostasis GO:0006874 9.78 HTR2C HTR2A DRD2
7 response to drug GO:0042493 9.65 SLC6A3 HTR2C HTR2A DRD2 COMT
8 negative regulation of adenylate cyclase activity GO:0007194 9.63 GRM3 DRD2
9 temperature homeostasis GO:0001659 9.63 HTR2A DRD2
10 myelination in peripheral nervous system GO:0022011 9.62 POU3F1 NRG1
11 response to iron ion GO:0010039 9.62 SLC6A3 DRD2
12 dopamine metabolic process GO:0042417 9.61 DRD2 COMT
13 regulation of synaptic vesicle exocytosis GO:2000300 9.61 HTR2A DTNBP1 DRD2
14 behavior GO:0007610 9.6 HTR2C HTR2A
15 behavioral response to cocaine GO:0048148 9.59 HTR2A DRD2
16 prepulse inhibition GO:0060134 9.58 SLC6A3 DRD2
17 release of sequestered calcium ion into cytosol GO:0051209 9.58 HTR2C HTR2A DRD2
18 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.56 HTR2A DRD2
19 dopamine biosynthetic process GO:0042416 9.55 SLC6A3 DAO
20 dopamine catabolic process GO:0042420 9.52 SLC6A3 COMT
21 adenohypophysis development GO:0021984 9.51 SLC6A3 DRD2
22 hyaloid vascular plexus regression GO:1990384 9.48 SLC6A3 DRD2
23 proline catabolic process GO:0006562 9.46 PRODH DAO
24 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.37 HTR2C HTR2A
25 regulation of dopamine secretion GO:0014059 9.33 HTR2A DTNBP1 DRD2
26 phospholipase C-activating serotonin receptor signaling pathway GO:0007208 9.32 HTR2C HTR2A
27 locomotory behavior GO:0007626 9.26 SLC6A3 NRG1 HTR2C DRD2
28 synapse assembly GO:0007416 8.92 NRXN1 NRG1 DRD2 BDNF

Molecular functions related to Schizophreniform Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.55 SLC6A3 NRXN1 NRG1 DRD2 BDNF
2 serotonin binding GO:0051378 9.32 HTR2C HTR2A
3 dopamine binding GO:0035240 9.26 SLC6A3 DRD2
4 Gq/11-coupled serotonin receptor activity GO:0001587 8.96 HTR2C HTR2A
5 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 8.62 HTR2C HTR2A

Sources for Schizophreniform Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....